AI Lead: Agentic Systems
Monte Rosa Therapeutics
AI Lead: Agentic Systems
Monte Rosa Therapeutics
Develops targeted protein degraders for therapy
Help to define and build Monte Rosa's agentic AI strategy and turn it into production systems that scientists use every day, from discovery through clinical development. This is a hands-on technical leadership role for someone who sees agents as the foundation of how scientific work gets done, not an add-on to existing software.
Compensation: 140000 to 175000 (CHF)
Develops targeted protein degraders for therapy
Monte Rosa Therapeutics develops molecular glue degraders (MGDs) to treat cancer and autoimmune/inflammatory diseases using its QuEEN discovery engine, a platform that fuses AI-guided chemistry, proteomics, and structural biology to design MGDs. MGDs work by bringing a target protein together with an E3 ligase, tagging the protein for destruction by the cell's proteasome rather than just inhibiting it. The company distinguishes itself with the QuEEN platform, partnerships with Roche and Novartis for joint development and funding, and a portfolio that includes MRT-2359, MRT-6160, and MRT-8102 as clinical-stage programs. Its goal is to discover, develop, and commercialize MGDs, grow its pipeline, and create value through collaborations, upfront payments, milestones, and royalties while delivering treatments for patients with serious diseases.
Explore more opportunities at Monte Rosa Therapeutics